[{"orgOrder":0,"company":"Epizyme","sponsor":"Transcenta Holding","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Capecitabine","moa":"||CLDN18","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Hutchmed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"HONG KONG","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tazemetostat","moa":"||Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Jefferies"},{"orgOrder":0,"company":"Epizyme","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"8","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Ipsen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Ipsen","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Ipsen"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Sponsor GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Epizyme \/ Sponsor GmbH"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Epizyme \/ Epizyme"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"EZM0414","moa":"SETD2","graph1":"Oncology","graph2":"Phase I","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase III","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epizyme \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epizyme \/ Inapplicable"},{"orgOrder":0,"company":"Epizyme","sponsor":"Pharmakon Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Pharmakon Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Pharmakon Advisors"},{"orgOrder":0,"company":"Epizyme","sponsor":"Swedish Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Swedish Cancer Institute","highestDevelopmentStatusID":"15","companyTruncated":"Epizyme \/ Swedish Cancer Institute"},{"orgOrder":0,"company":"Epizyme","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tazemetostat","moa":"Histone-lysine N-methyltransferase EZH2","graph1":"Oncology","graph2":"Phase I","graph3":"Epizyme","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Epizyme \/ Epizyme","highestDevelopmentStatusID":"6","companyTruncated":"Epizyme \/ Epizyme"}]
Find Clinical Drug Pipeline Developments & Deals by Epizyme
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
